IL5 and hypereosinophilic syndrome: There is also a lack of long-term real-world follow-up data beyond 1–2 years to assess potential predictors of response to mepolizumab, including HES subtype, peripheral blood eosinophil count, serum IL-5 and glucocorticoid sensitivity (21, 62).